Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline . SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 5, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). Investors suffering losses on their Altimmune investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal ri.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)

NEW YORK , May 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)

NEW YORK, NY / ACCESSWIRE / May 13, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=79475&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline

SAN DIEGO--(BUSINESS WIRE)---- $ALT #ALT--Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug.

Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). Altimmune investors have until July 5, 2024 to file a lead plaintiff motion. If you suffered a loss on your Altimmune i.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors

NEW YORK, May 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders

NEW YORK , May 9, 2024 /PRNewswire/ -- Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Altimmune, Inc. (NASDAQ: ALT) *please contact fletcher@fmoorelaw.com  The investigation concerns allegations of false and/or misleading statements, as well as a failure to disclose material facts, that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than investors were led to believe; and (iii) as a result of all the foregoing, defendants had overstated Altimmune's prospects for finding a strategic partner to develop pemvidutide. On February 13, 2024, Kerrisdale Capital published a report alleging that "a deeper examination of Altimmune's data reveals a drug with little chance of competing against either the approved incumbents or the other GLP-1 agonists progressing through clinical trials.

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=79075&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). Altimmune investors have until July 5, 2024 to file a lead plaintiff motion. Investors suffering losses on their Altimmune investments are encouraged to contact the Law Offices of Howard G. Smith t.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors

Amgen

AstraZeneca

Structure Therapeutics Inc

Merck

Pfizer

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

NEW YORK , May 8, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALT

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Altimmune investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities la.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) investors concerning the Company's possible violations of federal securities laws. On February 13, 2024, Kerrisdale Capital published a report alleging, among other things, that “a deeper examination of Altimmune's data reveals a drug with little chance of competing against either the approved incumbents or the other GLP-1 agonists p.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 13, 2024, Kerrisdale Capital published a report alleging, among other things, that “a deeper examination of Altimmune's data reveals a drug with little chance of co.

The Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024. SO WHAT: If you purchased Altimmune securities during the Class Period.

ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALT

Eli Lilly

Novo Nordisk

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALT

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:

Altimmune to Participate at Two Upcoming Conferences

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected passing.

Altimmune Statement on the Passing of Dr. Stephen Harrison

Scholar Rock Holding Corp

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

GoodRx Holdings

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.

News for Altimmune Stock (ALT)